Valye reports for unlimited access

CV Sciences, Inc. operates as a consumer wellness company focused on hemp-derived nutraceuticals and plant-based foods. Its product portfolio includes hemp extracts, cannabinoid-free supplements, plant-based protein products, and encapsulated softgels and tinctures. The company sells through diverse channels including retail stores, distributors, and e-commerce platforms across North America and Europe. Key brands include +PlusCBD™, +PlusHLTH™, Cultured Foods™, and Lunar Fox™. CV Sciences has made strategic acquisitions to expand its manufacturing and product capabilities, including Cultured Foods in Poland and Elevated Softgels in Colorado. The company emphasizes scientific validation, quality assurance, and regulatory compliance in its operations. It faces a competitive market landscape and evolving regulatory frameworks that influence its business environment.

Buda Juice, Inc. is a beverage company focused on producing and distributing UltraFresh™ cold-crafted citrus juices, lemonades, and wellness shots. Founded in 2013 and headquartered in Dallas, Texas, the company transitioned from retail storefronts to selling through grocery retailers, emphasizing a continuous cold chain from orchard to shelf to preserve freshness, taste, and nutrients. Its product portfolio includes organic wellness shots, value-forward non-organic citrus juices, and private label products. The company operates an asset-light model with a high-tech, SQF Level II certified production facility and outsources logistics. Buda Juice's strategic growth plan involves expanding its geographic footprint through a three-hub model serving large U.S. population centers. The company reported net income of $3.53 million for fiscal 2025 and maintains strong liquidity. It faces competition from larger beverage companies and depends on a limited number of customers while working to diversify its customer base.

WRAP TECHNOLOGIES, INC. operates as a global public safety technology and services company delivering integrated non-lethal solutions for law enforcement, corrections, defense, and public safety organizations. Its product portfolio centers on the BolaWrap non-lethal device line, designed to provide a controlled, non-pain-compliance option for officers to gain tactical advantage and reduce use-of-force incidents. Complementing hardware offerings are software platforms such as Wrap Reality VR training and WrapTactics digital training, aimed at enhancing officer readiness and decision-making under stress. The company also offers WrapVision, a body-worn camera and digital evidence management solution assembled in North America to meet federal procurement and data sovereignty requirements. Expanding into emerging markets, WRAP is developing counter-unmanned aircraft system (C-UAS) technologies leveraging proprietary tether deployment for non-lethal drone interdiction. The company’s sales approach integrates product sales with technology-enabled services, targeting U.S. federal, state, local, and international law enforcement agencies, correctional facilities, and defense sectors. Manufacturing is conducted domestically with a new facility in Virginia to support scalable production. WRAP holds a substantial intellectual property portfolio and pursues strategic partnerships to broaden market access and product integration.

Newsmax Inc. operates through its subsidiary Newsmax Media, which produces and distributes original news and editorial content via multiple platforms including cable TV channels (Newsmax, Newsmax2, World at War), syndicated radio shows, podcasts, digital websites, and print publications. The Broadcasting segment generates revenue from advertising, subscriptions, and affiliate fees from MVPDs, with distribution to over 100 million U.S. homes and international licensing in over 100 countries. The Digital segment generates revenue from online advertising, paid subscriptions (including Newsmax+ streaming service and specialized newsletters), and e-commerce sales of nutraceuticals and books. Newsmax Media's subsidiaries include Humanix Publishing, Medix Select (nutraceuticals), Newsmax Digital Advertising, Newsmax Publications (paid subscriptions), ROI Media Strategies (media buying services), and Crown Atlantic Insurance (insurance marketing). The company completed a private placement and IPO in 2025, raising significant capital and listing on the NYSE under ticker NMAX. Revenue has grown substantially from 2020 to 2025, with advertising and subscription revenues as key drivers. The company targets an older demographic with significant disposable income and continues to expand distribution and content offerings across traditional and digital platforms.

Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands and listed on Nasdaq under the ticker OACC. The company issues units consisting of Class A ordinary shares and redeemable warrants. The filings do not provide detailed information on the company's business operations, products, or customers. Financial disclosures focus primarily on liquidity and net income figures, with no reported revenue. The company has experienced changes in its chief financial officer position during 2025. It is classified as an emerging growth company under SEC rules.

PAINREFORM LTD., now operating as PRF Technologies Ltd., is a specialty pharmaceutical company originally focused on reformulating established therapeutics to provide extended post-surgical pain relief with reduced opioid use. In 2025, the company expanded into the clean energy sector through the acquisition of DeepSolar, an AI-driven solar analytics technology business. The company is headquartered in Tel Aviv, Israel, and prepares its financial statements under U.S. GAAP. It reported minimal revenue and a net loss for fiscal year 2025, with liquidity ratios indicating a moderate ability to cover short-term liabilities.

Quantum Biopharma Ltd. operates as a biotechnology company with a focus on developing pharmaceutical therapies for neurodegenerative diseases. Its primary product candidate is Lucid-MS, a patented molecular compound targeting multiple sclerosis. The company conducts research and development through subsidiaries including Huge Biopharma in Australia and Lucid. It has paused some research programs due to funding constraints and suspended cannabis-related operations through FV Pharma. The company licenses intellectual property to Unbuzzd Wellness Inc. and Celly U.S. for consumer product commercialization, maintaining significant influence over Unbuzzd. Quantum Biopharma has no approved pharmaceutical products or commercial sales and continues to incur losses while funding operations through equity and debt financing. It holds a significant portion of its assets in cryptocurrency, which introduces financial statement volatility. The company is advancing Lucid-MS toward regulatory filings and clinical trials and is involved in ongoing litigation that could materially impact its financial condition. It rents office space in Toronto and does not own significant physical infrastructure [S1][S2].

Nyxoah SA develops and commercializes the Genio system, a medical device for treating obstructive sleep apnea (OSA). The company is headquartered in Belgium and has a senior management team with extensive experience in medical devices and commercialization. Nyxoah has expanded its commercial footprint with the launch of the Genio system in the Netherlands and has obtained favorable reimbursement rulings to support market access. The company finances its operations through equity and debt instruments, including convertible notes issued in late 2025. Financial disclosures indicate ongoing net losses as the company invests in commercialization and clinical development.

Evogene Ltd. is a biotechnology company headquartered in Israel, with a focus on developing and commercializing products in agriculture and human health. The company operates through subsidiaries including Biomica Ltd., which develops microbiome-based therapeutics, and Lavie Bio Ltd., which focuses on bio-fungicides. Evogene's business model includes licensing proprietary technologies and products to third parties, such as the exclusive worldwide license of BMC128 to Shanghai Lishan Biopharmaceuticals for cancer therapeutics. The company also engages in collaborations and consortiums to advance research in genome editing and precision agriculture. Evogene maintains a proprietary computational platform (CPB) that integrates big data and AI algorithms to support its R&D efforts. The company has received various government grants and participates in international research programs, which come with regulatory and royalty obligations under Israeli law. Financially, Evogene reported revenues of approximately $3.85 million and a net loss of $7.83 million for the fiscal year ended December 31, 2025, with a strong liquidity position evidenced by a current ratio of 4.54 and cash ratio of 3.76.

Nexa Resources S.A. operates integrated mining and smelting businesses focused on zinc, copper, silver, lead, and gold. The company’s mining operations produce concentrates that are either sold externally or supplied internally to its smelting operations. Smelting generates revenue from processing concentrates, capturing value from treatment charges, free metal, premiums, and by-products. Nexa’s sales are diversified geographically, with significant exposure to Peru, Brazil, the United States, and Asia. The company holds a large portfolio of mining concessions in Peru and Brazil, with ongoing exploration and project evaluation activities. Capital expenditures focus on sustaining current operations and advancing growth projects. Nexa manages financial risks through a comprehensive risk management framework and maintains liquidity through cash reserves and access to credit facilities. The company follows a dividend policy linked to free cash flow generation.

YPF SOCIEDAD ANONIMA operates a fully integrated oil and gas business in Argentina, with leading market positions across upstream, midstream, downstream, LNG, integrated gas, and new energies segments. The company’s hydrocarbon production is concentrated in the Neuquina, Golfo San Jorge, Austral, and Noroeste basins. As of December 31, 2025, YPF held substantial developed and undeveloped acreage, with a portfolio of exploration permits and exploitation concessions operated and non-operated. The company engages in joint ventures and contractual arrangements with varying ownership interests. In 2025, YPF drilled multiple wells and maintained active development and exploratory activities. Financially, the company reported $18.448 billion in revenue and a net loss of $799 million for the fiscal year ended December 31, 2025, with liquidity ratios below 1 indicating some short-term liquidity constraints. Recent news highlights operational developments including rig lease deals and strategic asset sales, as well as challenges such as lower hydrocarbon production impacting earnings.

Inspira Technologies OXY B.H.N. Ltd, headquartered in Israel, develops innovative medical devices aimed at transforming respiratory care, particularly as an alternative to mechanical ventilation. Its flagship product, the INSPIRA ART100 system, oxygenates and circulates blood extracorporeally, allowing patients to remain awake and avoid complications associated with mechanical ventilators. The system has received FDA 510(k) clearance for specific cardiopulmonary bypass procedures and is integrated with the HYLA blood sensor for continuous real-time monitoring. The company pursues a global go-to-market strategy involving regulatory approvals, collaborations with leading medical centers, and strategic distribution partnerships. Recent commercial milestones include securing multi-million dollar purchase orders and vendor approvals enabling deployment in major healthcare networks. Financially, the company reported initial revenues in 2025 but continues to operate at a net loss, investing heavily in research, development, and commercialization efforts.

Mag Magna Corp is engaged in the rare earth minerals mining industry, having acquired its initial mining properties in January 2026. The company plans to acquire and develop undeveloped rare earth mineral mining properties and conduct mining operations. Previously, the company was involved in the chicken farming industry but has ceased pursuing that business. Recent strategic moves include the acquisition of a large-scale poultry farming enterprise, the launch of a smart poultry technology platform, and securing a major multi-year supply contract. The company has also undertaken supply chain integration and capital collaboration initiatives. Leadership changes include the appointment of new board members and officers in early 2026. Financially, the company reported no revenue and a net loss for the latest period, with limited liquidity and significant current liabilities. The company has entered into equity purchase agreements and convertible promissory notes to support working capital needs.

H.B. Fuller Company, founded in 1887 and incorporated in 1915, is a leading global formulator, manufacturer, and marketer of adhesives, sealants, and specialty chemical products. The company serves diverse industries including consumer goods, construction, industrial manufacturing, aerospace, defense, electronics, and automotive sectors. Its products improve customer product performance and manufacturing processes. H.B. Fuller operates in 34 countries with manufacturing, sales, and distribution facilities, and maintains a broad portfolio of products and customers. The company emphasizes innovation through research and development, sustainability, and regulatory compliance. It operates through three segments: Hygiene, Health and Consumable Adhesives; Engineering Adhesives; and Building Adhesive Solutions, following a reorganization in fiscal 2025. The company employs approximately 7,100 people worldwide and focuses on a collaborative and inclusive culture.

Dixie Group Inc is a manufacturer and distributor of floorcovering products, primarily soft floorcoverings such as carpets and rugs made from nylon and polyester yarns. The company also offers luxury vinyl flooring and wood products sourced mainly from overseas. Its business is largely dependent on the residential replacement market, which is sensitive to economic conditions and housing activity. The company faces intense competition from both domestic and foreign manufacturers and distributors. It has been impacted by tariffs and trade policies, which have increased costs and pressured margins. Dixie Group has significant indebtedness with covenants that pose risks to its financial stability. The company was delisted from Nasdaq in 2024 and now trades on the OTCQB market, which may affect liquidity and capital raising. It relies on sophisticated information systems and is subject to environmental and regulatory compliance costs. Recent news highlights efforts to focus on growth amid challenges and improvements in earnings per share in recent quarters [S1][S2][N1][N2][N3].

Oil States International, Inc. operates globally in the oil and gas sector, providing specialty products and services through three main segments: Offshore Manufactured Products, Completion and Production Services, and Downhole Technologies. The company serves resource-intensive regions worldwide, including the U.S., West Africa, the North Sea, the Middle East, South America, and Asia. Revenue recognition is split between point-in-time and over-time methods, with significant project-driven contracts recognized over time using cost-to-cost input measures. The company had a backlog of $322.5 million as of the end of 2025, with a portion expected to be recognized in 2026. The company reported a net loss in 2025, driven in part by asset impairments, and maintains liquidity through cash reserves and credit facilities. It manages foreign currency risk operationally and through financial instruments as needed. Research and development expenses are modest and included in cost of revenues.

Orgenesis Inc. is a global biotechnology company focused on developing and commercializing cell and gene therapies (CGTs) through a decentralized cell processing (DCP) platform. This platform enables automated, standardized, and scalable production of advanced therapy medicinal products (ATMPs) near patient care sites, aiming to reduce costs and logistical complexities associated with traditional centralized manufacturing. The company’s business model includes partnerships with hospitals, research centers, and industry players to provide POCare services and out-license therapies. Orgenesis operates multiple subsidiaries worldwide engaged in R&D, production, and management services. Its product portfolio includes platforms for pancreatic islets, CAR-T therapies, stromal vascular fraction, oncolytic viruses, tumor-infiltrating lymphocytes, hematopoietic stem cells, dendritic vaccines, induced pluripotent stem cells, and exosomes. The company reported revenues of approximately $1.035 million in 2024, primarily from development services and licensing fees. However, Orgenesis faces significant financial challenges, including a net loss of $48.2 million in 2024, very low liquidity, and substantial doubt about its ability to continue as a going concern without additional capital. The company has taken corporate actions such as a 1-for-10 reverse stock split and trading on OTC markets, with recent board expansions and clinical data releases for its CAR-T therapy. Orgenesis continues to develop a diverse pipeline of therapies targeting cancer and other diseases, leveraging its DCP platform to improve cost-effectiveness and accessibility.

Linkhome Holdings Inc. operates an AI-powered real estate platform, HomeGPT, designed to streamline and enhance the home buying and selling process. The platform integrates AI technology with financial innovation to offer services including brokerage, cash purchase offers, mortgage facilitation, and property management. The company’s Cash Offer product enables competitive all-cash bids by purchasing properties directly and reselling to buyers after financing is secured. Flash Sell allows sellers to quickly sell homes with reduced fees and without traditional listing hassles. Linkhome’s Buy Before Sell service provides flexibility for clients transitioning between homes. The platform aggregates over 1 million active residential listings and has facilitated over $180 million in transactions since 2021. The company completed its IPO in July 2025 and focuses on expanding its market presence beyond California while enhancing its AI capabilities and service offerings.

Provectus Biopharmaceuticals, Inc. focuses on developing immunotherapy drug candidates based on rose bengal sodium (RBS), a synthetic small molecule with multi-mechanistic immune effects. The company’s proprietary pharmaceutical-grade RBS is used in various clinical and non-clinical programs targeting oncology, dermatology, ophthalmology, hematology, wound healing, and veterinary applications. Provectus holds a broad portfolio of U.S. and international patents protecting its technology. Clinical development includes intratumoral PV-10 for cancers such as melanoma and pancreatic cancer, topical PH-10 for dermatologic conditions, and PV-305 for ocular diseases. The company also pursues early drug discovery and computer modeling programs. Manufacturing processes for RBS API and drug candidates follow stringent quality standards and have been reviewed by multiple regulatory agencies. Provectus has launched VisiRose, a clinical-stage startup to commercialize ocular research. Financially, the company reported a net loss and limited liquidity as of the end of 2025.

Journey Medical Corp is a U.S.-based commercial-stage pharmaceutical company specializing in FDA-approved prescription drugs for dermatological conditions. Its product portfolio includes oral and topical treatments for rosacea, acne, primary axillary hyperhidrosis, fungal infections, and pruritus. The company acquires rights to products through licensing or acquisition and commercializes them via its field sales organization. It is a controlled subsidiary of Fortress Biotech, Inc. Key marketed products include Emrosi (oral minocycline for rosacea), Qbrexza (topical cloth for hyperhidrosis), Accutane (oral isotretinoin for severe acne), Amzeeq and Zilxi (topical minocycline foams). The company reported $61.858 million in revenue and a net loss of $11.431 million for the fiscal year ended December 31, 2025. It maintains a strong patent portfolio protecting its products and is focused on expanding payer coverage and prescription demand.

Marblegate Capital Corp is engaged in the operation and financing of taxi fleets primarily in New York City. Its business model includes managing a large taxi fleet, providing loans secured by taxi medallions, and operating taxi clubhouses for drivers. The company uses fair value accounting for its loan portfolio, which is subject to significant estimates due to the illiquid nature of taxi medallions and regulatory factors. It has executed credit facilities and term loans to finance fleet expansion and strategic initiatives. Leadership changes and board appointments have been announced recently. The company faces industry-specific risks including regulatory changes, medallion value fluctuations, and loan performance.

Guerrilla RF, Inc. is a fabless semiconductor company founded in 2013 and headquartered in Greensboro, North Carolina. The company designs and markets high-performance monolithic microwave integrated circuit (MMIC) products targeting underserved markets in wireless infrastructure, automotive, and catalog segments. Its wireless infrastructure products support 5G networks and satellite communications, while automotive offerings meet stringent industry standards for connectivity solutions. The company outsources wafer fabrication and assembly to subcontractors in Taiwan, Singapore, Malaysia, and the United States, utilizing GaAs, GaN, and SOI CMOS process technologies. Guerrilla RF sells primarily through independent distributors and maintains a global customer base exceeding 300 end customers. The company invests significantly in research and development to expand its product portfolio and maintain competitive performance.

Cognition Therapeutics Inc focuses on discovering and developing innovative small molecule therapeutics for age-related degenerative diseases affecting the central nervous system and retina. Its lead candidate, zervimesine (CT1812), is designed to protect neuronal synapses by preventing the binding of toxic protein oligomers implicated in Alzheimer's disease and dementia with Lewy bodies. The company has completed Phase 2 clinical trials and is conducting ongoing studies in early-stage Alzheimer's and other indications. Clinical development has been supported by substantial grant funding primarily from the National Institute on Aging. The company retains worldwide rights to zervimesine and plans to pursue regulatory approvals in major markets, potentially leveraging strategic partnerships. Cognition Therapeutics operates as a clinical-stage company with no approved products and has incurred significant losses since inception.

Celcuity Inc. is a clinical-stage biotech focused on developing targeted therapies for solid tumors. Its lead candidate, gedatolisib, is an intravenous kinase inhibitor that comprehensively inhibits the PI3K/AKT/mTOR pathway by targeting all class I PI3K isoforms and mTOR complexes. This mechanism differentiates it from other therapies that target single components of the pathway. The company is conducting multiple clinical trials, including Phase 3 studies in hormone receptor-positive, HER2-negative advanced breast cancer and a Phase 1b/2 trial in metastatic castration resistant prostate cancer. Gedatolisib has received FDA Fast Track and Breakthrough Therapy designations and is under Priority Review by the FDA following NDA acceptance in January 2026. Celcuity has not yet commercialized any products and has incurred significant losses, financing operations through equity and debt. The company maintains strong liquidity but carries substantial indebtedness with associated risks.

Sypris Solutions Inc is a manufacturing and engineering services company serving critical infrastructure sectors including energy, aerospace, defense, and transportation. The company operates through two main segments: Sypris Technologies, which supplies forged and machined steel components primarily for commercial vehicles and energy pipelines, and Sypris Electronics, which provides circuit card and box build manufacturing for aerospace and defense electronics. Sypris maintains multi-year, often sole-source contracts with major OEMs and defense contractors, focusing on technological innovation, quality, and cost efficiency. The company’s operations are primarily in North America, including a Mexican subsidiary. Sypris faces competitive pressures in both industrial manufacturing and aerospace electronics markets and manages supply chain challenges, including component lead times and tariffs. The company’s strategy emphasizes expanding multi-year customer relationships, investing in advanced manufacturing capabilities, and pursuing strategic acquisitions to enhance its market position and operational efficiency.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system disorders. Founded by experts in psychiatry and neuroscience, the company focuses on circuit-specific pharmacotherapies that target neural circuits linked to disease. Its lead product candidate, ML-007C-MA, combines an M1/M4 muscarinic agonist with a peripherally acting anticholinergic to treat schizophrenia and Alzheimer's disease psychosis. The company has conducted multiple Phase 1 trials and is currently running Phase 2 trials with planned topline results in 2026 and 2027. MapLight completed its IPO in October 2025, raising significant capital to fund ongoing research and development. The company operates primarily in the United States with leased facilities in California and Massachusetts.

Rockwell Medical, Inc. develops, manufactures, and distributes hemodialysis concentrates and ancillary products used in the treatment of end-stage kidney disease. The company operates manufacturing facilities in Michigan, Texas, and Iowa, and delivers products primarily to dialysis clinics in the United States and abroad. Rockwell's products are regulated by the FDA and adhere to quality standards including ISO 13485 and cGMP. The company focuses on maintaining high product quality, reliability, and customer service. Rockwell's business is concentrated in the hemodialysis market segment, with a significant portion of sales to a small group of customers, including DaVita, which accounted for 16% of net product sales in 2025. The company has been implementing operational efficiencies, including facility closures and equipment upgrades, to improve margins and streamline production.

MetaVia Inc. operates as a clinical-stage biotechnology company developing pharmaceuticals targeting cardiometabolic diseases, with a focus on obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidates are DA-1726, a long-acting dual-incretin peptide, and vanoglipel (DA-1241), both exclusively licensed from Dong-A ST Co., Ltd. The company has reported positive clinical trial results demonstrating safety, tolerability, and efficacy signals such as weight loss and metabolic improvements. MetaVia maintains a comprehensive global patent portfolio protecting its product candidates and their therapeutic uses. The company has experienced significant operating losses and negative cash flows since inception and has not generated any revenue. It funds operations primarily through equity offerings and collaborations. MetaVia's business model centers on advancing clinical development and securing regulatory approvals for its product candidates, with ongoing efforts to manage intellectual property, manufacturing partnerships, and capital resources.

Freightos Ltd is a technology company providing a digital platform for international freight shipping. Its platform facilitates spot transactions between buyers and sellers, primarily serving smaller importers/exporters and niche e-commerce vendors. The company generates revenue through subscription-based SaaS solutions and transaction fees on its platform, including customs brokerage services. Freightos operates globally with a diverse workforce and invests heavily in research and development, sales, and marketing. The business experiences seasonal fluctuations aligned with global trade patterns and is influenced by external factors such as geopolitical conflicts, trade wars, and shipping disruptions. The company reported a net loss for the fiscal year ended 2025 and is executing a cost optimization plan to improve profitability. Leadership changes include the appointment of a new CEO in early 2026.

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company developing small molecule drugs that target the A3 adenosine receptor, aiming to treat inflammatory diseases and cancers. The company’s business model centers on advancing its drug candidates through clinical trials and generating revenues primarily from out-licensing agreements, milestone payments, and potential royalties. Its lead candidates include Piclidenoson, in a Phase III trial for psoriasis, and Namodenoson, in Phase III for hepatocellular carcinoma and Phase IIb for MASH, with a completed Phase IIa pancreatic cancer study showing positive safety results. The company also has veterinary licensing agreements, such as with Vetbiolix for Piclidenoson in osteoarthritis in companion animals. Financially, Can-Fite reported revenues of $0.41 million and net losses reflecting ongoing R&D investments. It maintains liquidity with over $5 million in cash and a strong current ratio. Recent patent allowances and capital raises support its clinical development pipeline [S1][N2][N3][N4][N5].

Allot Ltd. operates in the cybersecurity sector, with a focus on network security and cybersecurity as a service (SECaaS). The company is headquartered in Hod-Hasharon, Israel, and files annual and quarterly reports with the U.S. SEC. Its business model includes providing cybersecurity solutions, including mobile cybersecurity services, supported by partnerships such as with Compax Venture. The company reported full year 2025 revenue of approximately $102 million and net income of $3.7 million, with a strong liquidity position as of the end of 2025. Recent market commentary notes share price appreciation and competitive positioning within the cybersecurity industry.

Marchex harnesses artificial intelligence and conversation intelligence to transform business conversations into actionable insights, enabling organizations to optimize customer acquisition and experience. Its product portfolio includes Marketing Edge for marketing attribution, Sonar Business Text Messaging for AI-powered messaging, Marchex Platform Services for API-based conversation intelligence, Spotlight for multi-location business analytics, Engage for sales engagement, and AI-driven Call Summary and Sentiment Suite. The company primarily operates in the U.S. and targets B2B2C vertical markets, serving both large enterprises and small businesses. Marchex's technology platform supports high volumes of calls and texts and integrates with existing communication and CRM systems. The company employs a transparent pricing model based on conversation volume and maintains partnerships with major technology and CRM providers. The market is highly competitive and rapidly evolving, with seasonality impacting call volumes. Marchex pursues selective acquisitions to enhance its strategic position and product offerings.

CollPlant Biotechnologies Ltd operates in regenerative and aesthetic medicine, leveraging its proprietary recombinant human collagen (rhCollagen) produced in genetically engineered tobacco plants. The company’s technology platform supports a broad pipeline of products including medical aesthetics dermal fillers, 3D-bioprinted tissues and organs, and bioinks for regenerative medicine applications. CollPlant collaborates with AbbVie on dermal and soft tissue fillers, receiving milestone payments tied to clinical development. It also develops photocurable dermal fillers and 3D-bioprinted regenerative breast implants, with preclinical and non-clinical studies showing encouraging results. The company markets rhCollagen-based bioinks and has a manufacturing and supply agreement with STEMCELL Technologies. Distribution has expanded into North America with a new logistics center. CollPlant’s financials for 2025 show modest revenue and ongoing net losses, with liquidity supported by cash and current assets exceeding current liabilities [S1, S2, N1, N7].

ParaZero Technologies Ltd. is an Israeli aerospace and defense technology company founded in 2014, focused on developing safety, protection, and mitigation solutions for unmanned aerial systems (UAS). The company addresses key barriers to drone adoption by providing autonomous safety mechanisms and real-time flight monitoring to reduce risks to people, property, and critical infrastructure. ParaZero has expanded its offerings to include counter-UAS (C-UAS) solutions designed to detect, identify, and mitigate hostile drone threats, particularly in defense and homeland security sectors. Its product portfolio includes the SafeAir autonomous parachute safety system and the DefendAir net-based kinetic interception system. The company operates a multi-tiered business model selling directly to OEMs, ODMs, end users, and through resellers and online channels. ParaZero's technology is protected by global patents developed over more than a decade, supporting its competitive positioning in a fragmented and evolving market. The company is headquartered in Israel and employs 22 full-time staff.

Golar LNG Ltd is an energy company specializing in floating liquefied natural gas (FLNG) technology and operations. The company owns and operates FLNG vessels including FLNG Hilli and FLNG Gimi, generating revenues through long-term contracts for liquefaction services and sales-type leases. In 2025, Golar LNG completed the commercial operation of FLNG Gimi and exited traditional shipping operations. The company is undertaking significant capital projects including the refurbishment of FLNG Hilli and conversion of the MKII FLNG unit, both supported by long-term contracts. Golar LNG maintains a strong liquidity position with over $1.15 billion in cash and equivalents as of the end of 2025. A strategic review was initiated in early 2026 to explore alternatives to accelerate growth and maximize shareholder value. The business faces risks related to project execution, customer concentration, and capital access.

Ferroglobe PLC operates as a leading global producer of silicon metal, silicon-based alloys, and manganese-based specialty alloys. The company serves multiple geographic regions including North America, Europe, and South Africa. Its product portfolio includes silicon metal, silicon-based alloys, and manganese-based alloys, which are used in various industrial applications such as steel production and chemical manufacturing. The company’s operations are influenced by global trade policies, energy costs, and market demand dynamics. Ferroglobe has implemented safeguard measures in the EU and is involved in trade cases in the U.S. to address import competition. The company maintains a strong liquidity position and has a strategic focus on cost control, operational flexibility, and sustainability initiatives including a decarbonization plan.